Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
AbCellera Biologics Inc. (ABCL) had Stock-Based Compensation of $67.58M for the most recently reported fiscal quarter, ending 2024-12-31.
| Income Statement Financials | |
$5.05M |
|
$-34.21M |
|
-- |
|
$5.05M |
|
$77.80M |
|
$-72.75M |
|
$25.93M |
|
$-46.83M |
|
$-46.83M |
|
$-34.21M |
|
$-34.21M |
|
$-34.21M |
|
$-34.21M |
|
$-72.75M |
|
$-58.85M |
|
294.33M |
|
294.33M |
|
$-0.11 |
|
$-0.11 |
|
| Balance Sheet Financials | |
$751.37M |
|
$340.43M |
|
$609.18M |
|
$1.36B |
|
$76.61M |
|
-- |
|
$227.86M |
|
$304.47M |
|
$1.06B |
|
$966.16M |
|
$1.06B |
|
295.76M |
|
| Cash Flow Statement Financials | |
$-108.56M |
|
$121.41M |
|
$12.77M |
|
$160.61M |
|
$183.62M |
|
$23.00M |
|
|
Stock-Based Compensation |
$67.58M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
9.81 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-1440.98% |
|
-1440.98% |
|
-- |
|
-927.49% |
|
-677.56% |
|
$-186.95M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
0.15 |
|
599.22 |
|
-3.24% |
|
-3.54% |
|
-2.51% |
|
-3.24% |
|
$3.57 |
|
$-0.64 |
|
$-0.37 |
|